Trials / Unknown
UnknownNCT06325826
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Egyptian Liver Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | General Evaluation Score (GES) | According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points) |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2023-06-30
- Completion
- 2025-06-30
- First posted
- 2024-03-22
- Last updated
- 2024-03-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06325826. Inclusion in this directory is not an endorsement.